PE-22-28

updated

PE-22-28 is a seven-amino-acid fragment (GVSWGLR) of the sortilin propeptide, a shortened version of the research peptide spadin, studied as an antidepressant. Vendors sell it for mood and cognition as 300 to 500 times stronger than spadin, lasting about 23 hours. In mice one injection cut forced-swim immobility from 161.7 to 91.8 seconds, but every paper comes from one French CNRS laboratory, no human has received it, and the 23-hour figure was measured on modified analogues. Graded C for genuine cell and mouse work.

seven-residue sortilin-propeptide fragment

  • Sequence GVSWGLR
  • Also called a shortened spadin or mini-spadin analogue
  • TREK-1 inhibition shown in vitro
  • No human administration study identified

Which molecule is PE-22-28?

Base PE-22-28 is GVSWGLR. G/A-PE-22-28 replaces the first glycine with alanine, and biotinylated G/A-PE-22-28 adds another modification. These forms cannot share duration or potency claims by default.

Does PE-22-28 last 23 hours?

That number came from a mouse behavioral figure for a high-dose biotinylated G/A analogue. The base GVSWGLR peptide was not shown to have a 23-hour human half-life or effect.

source: Primary paper · cells and mice, Djillani A et al. Frontiers in Pharmacology, 2017.

source: Primary paper · cells and mice

source: US11220527 · analogue claims, US Patent 11,220,527.

Has PE-22-28 treated depression in people?

No administered-human trial was identified. The depression claim rests on mouse behavioral models and cell assays, not clinical symptom remission, function, relapse prevention, or comparative treatment evidence.

source: PubMed and registry · no human trial, PubMed and ClinicalTrials.gov.

source: Primary paper · cells and mice

What does the research actually show?

PE-22-28 blocked TREK-1 currents in a transfected-cell assay and changed several mouse behavioral and neural-plasticity measures. The cited studies do not show an antidepressant effect in people.

Forced-swim immobility and novelty-suppressed feeding are experimental readouts. Neither is a diagnosis of depression or a validated substitute for a clinical outcome.

source: Primary paper · cells and mice

source: Follow-up paper · nonhuman evidence, Borsotto M et al. 2019.

What is known about human safety?

Human pharmacokinetics, cardiac electrophysiology, neurologic effects, suicidality, mania risk, interactions, immune reactions, pregnancy, and repeated exposure are not characterized for PE-22-28.

TREK-1 channels participate in neuronal excitability and other physiology. Cell selectivity assays do not establish whole-person safety, especially with psychoactive medicines or mood disorders.

source: PubMed and registry · no human trial

source: Primary paper · cells and mice

Is PE-22-28 approved?

No FDA-approved PE-22-28 drug, prescribing label, or registered human trial was identified.

source: PubMed and registry · no human trial

source: US11220527 · analogue claims

Studies and sources

Primary paper · cells and mice

Cell and animal study

Djillani A et al. Frontiers in Pharmacology, 2017.

PE-22-28 inhibited human TREK-1 channels in a transfected-cell assay and changed forced-swim, novelty-suppressed-feeding, neurogenesis, and synaptogenesis measures in mice or mouse cells. Figure-level data assign the 14-to-23-hour half-time effects to G/A-PE-22-28 and biotinylated G/A analogues, not unmodified PE-22-28.

Participants / model
Transfected HEK cells, mouse neurons, and mice
Treatment
PE-22-28 plus multiple modified analogues
Follow-up
Acute or four-day mouse experiments
Study design
In-vitro channel assays and animal behavioral studies
Read the original source
Follow-up paper · nonhuman evidence

Preclinical study

Borsotto M et al. 2019.

The follow-up publication is preclinical and does not report administered-human efficacy, pharmacokinetics, or safety.

Participants / model
Experimental nonhuman systems
Treatment
PE-22-28 research intervention
Study design
Preclinical study
Read the original source
US11220527 · analogue claims

Patent

US Patent 11,220,527.

The patent describes PE-22-28-related sequences and focuses development claims on modified analogues, including the glycine-to-alanine form. A patent is applicant-written and does not establish human efficacy or safety.

Study design
Patent disclosure

Used for analogue identity and development context only.

Read the original source

Why is PE-22-28 in C tier?

The C grade reflects TREK-1 cell assays and direct mouse behavioral studies. No administered-human study establishes antidepressant efficacy, duration, or safety.

how tiers are graded: methodology · every cited source · about reptides.

Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.